Independence Day 2025: PM Narendra Modi makes 10 big announcements
On the occasion of India's 79th Independence Day, Prime Minister Narendra Modi addressed the nation from the Red Fort on Friday, unveiling 10 major announcements spanning national security, economic reforms, defence, and employment.
Modi reaffirmed a tough stance on national security, declaring on the Indus Waters Treaty that 'blood and water won't flow together' and emphasising 'zero tolerance to terror' through deep strikes under Operation Sindoor. The Prime Minister also announced a new defence doctrine, pledging to retaliate 'on our terms.'
In the defence sector, he revealed plans for Made-in-India fighter jet engines and a broader push for self-reliance under the Atmanirbhar Bharat initiative. The government will also launch the 'Samudra Manthan' mission to boost domestic oil and gas exploration.
On the economic front, Modi said GST 2.0 would be rolled out by Diwali with lower rates and reduced compliance, while linking recent credit rating upgrades to growing global trust in India. He assured the agricultural community that there would be no anti-farmer, fisher, or dairy policies.
The Prime Minister also announced the launch of a Rozgar Yojana aimed at creating one crore jobs across sectors, underscoring employment as a key priority.
These announcements set the tone for the government's strategic and economic agenda in the coming months, with a focus on national strength, economic growth, and social welfare.
Ahmedabad Plane Crash
News desk at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Trump says no imminent plans to penalize China for buying Russian oil
WASHINGTON (Reuters) -U.S. President Donald Trump said on Friday he did not immediately need to consider retaliatory tariffs on countries such as China for buying Russian oil but might have to "in two or three weeks." Trump has threatened sanctions on Moscow and secondary sanctions on countries that buy its oil if no moves are made to end the war in Ukraine. China and India are the top two buyers of Russian oil. The president last week imposed an additional 25% tariff on Indian goods, citing its continued imports of Russian oil. However, Trump has not taken similar action against China. He was asked by Fox News' Sean Hannity if he was now considering such action against Beijing after he and Russian President Vladimir Putin failed to produce an agreement to resolve or pause Moscow's war in Ukraine. "Well, because of what happened today, I think I don't have to think about that," Trump said after his summit with Putin in Alaska. "Now, I may have to think about it in two weeks or three weeks or something, but we don't have to think about that right now. I think, you know, the meeting went very well." Chinese President Xi Jinping's slowing economy will suffer if Trump follows through on a promise to ramp up Russia-related sanctions and tariffs. Xi and Trump are working on a trade deal that could lower tensions - and import taxes - between the world's two biggest economies. But China could be the biggest remaining target, outside of Russia, if Trump ramps up punitive measures. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Does India Need Tesla Now as Much as It May Have a Few Years Ago?
Tesla opens two official stores in India, years after various efforts to enter the country while also avoiding the massive import tariffs on foreign-made vehicles. Tesla CEO Elon Musk has met with Indian Prime Minister Narendra Modi a number of times regarding building a gigafactory in India, but the discussions have not resulted in a positive outcome for the country. Tesla now offers only the Model Y in India, assembled in China, but now lacks the attention and political will to build a full-size plant in the country of over one billion people, as India's domestic automakers catch up. For a country with over a billion people, India has remained largely uninterested in Tesla for a long time. Or so it seemed. Every few years we heard rumors of overtures made by Tesla's team to India's government, wanting to be the site of Tesla's future gigafactories, but after a few weeks of hopeful forward-looking political niceties nothing would materialize. The last time India was seen as being among the finalists for a Tesla Gigafactory was in 2023, as Elon Musk teased that he was looking at a number of countries for the next site, including Canada. But 2023 was also a very different time for Tesla and for Elon Musk, no matter how close it seems. At the time, India's Prime Minister Narendra Modi even reported to have made a personal push for Gigafactory India, which would have given Tesla not only tremendous regional export potential, but also longer-range export potential to Europe. In the end, nothing came of that particular effort in 2023, though India did once again pop up in mid-February of this year as CEO Elon Musk met privately with Prime Minister Modi, amid rumors of another push for a Tesla gigafactory in India. Attractive Electric Micromobility Network One of the reasons India has been among the finalists for Tesla's next plant is its population of 1.45 billion, and India has a very advanced electric micromobility network, making it suitable to host thousands of Tesla Supercharger sites. Also, Tesla in 2023 was still reportedly considering a $25,000 model, which would have been a popular version for India and for regional export. The eventual demise of that model, believed to have been felled by a number of factors including inflation, seemingly closed the door on Gigafactory India as well. One major sticking point during all of these negotiations—at least as it concerns an official launch if not local manufacturing—was a waiver from India's very high import duties, which had effectively kept out many Tesla vehicles, even through the gray market. Now, Tesla appears to be inching closer to an official sales launch in the country if not local manufacture—a business case that seems to have eroded relatively quickly over the past two years. For starters, Tesla would need the money to build the factory in India, and its financial picture is seen as having steadily eroded throughout 2025. Stores in Delhi and Mumbai? Nevertheless, Tesla has just opened a showroom in Delhi and has leased several pieces of land in nearby cities. A Supercharger location has been built near the Delhi site as well, with more planned for neighboring cities. Overall, Tesla reportedly plans one store in Delhi and one in Mumbai, and so far the only model on sale in the country is the Model Y, which is made in China. It's not quite the big, official launch, but something closely resembling the arrival of a western luxury brand in China in the 1990s, and without local manufacturing presence. The Model Y in India, therefore, is bound to be a pricey, rare, rich person's car with just a couple of official company stores located far apart—quite different from what was envisioned a few years ago. And it won't be an offering for the middle class, like it is in China or Europe. When it comes to local manufacturing, those chances now seem lower than just two years ago when the Berlin-Brandenburg plant was at least meeting European demand. That demand abruptly cratered due to a significant dip in Elon Musk's popularity in a number of western European countries and remains unlikely to be regained anytime soon. Likewise, Tesla appears to be done building gigafactories in far-off foreign countries for the time being, at least barring major political changes. More importantly, Tesla no longer appears to have the capital to devote to such a venture, nor any new (and actually affordable) models to offer India, while also facing a thin middle class not willing to spend money on anything the automaker has in its lineup at the moment. Those major political changes may well turn out to be China's quick assimilation of the EV market in scores of developing countries in Southeast Asia and South America, both of which disfavor Tesla's regional ambitions on the Indian subcontinent. We are also likely to see India's domestic automakers, Mahindra and Tata among them, break out of a largely domestic market and offer their own affordable and desirable EVs that can be exported—something which is already happening. India, it appears, may not need Tesla as it did just a few years ago. Does Tesla need new, less expensive vehicles in its lineup, beyond the Model 3 and Model Y? Let us know what you think in the comments below.
Yahoo
6 hours ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
